Simões e Silva Ana C, Diniz José Silvério S, Pereira Regina M, Pinheiro Sérgio V Brant, Santos Robson Augusto S
Department of Pediatrics, Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, MG, 30130-100, Brazil.
Pediatr Res. 2006 Dec;60(6):734-9. doi: 10.1203/01.pdr.0000246100.14061.bc. Epub 2006 Oct 25.
The aim of the present study was to evaluate plasma renin activity (PRA) and Angiotensin (Ang) levels [Ang I, Ang II and Ang-(1-7)] to examine the circulating Renin-Angiotensin System (RAS) in renal disease among children with different forms and stages of chronic renal failure (CRF). Subjects were divided as follows: 32 normotensive healthy subjects, 23 normotensive CRF subjects, 34 hypertensive CRF subjects and 21 subjects with end-stage renal disease (ESRD). Radioimmunoassays for PRA (ngAngI/mL/h) and angiotensin (pg/mL) measurements were performed on all subjects. PRA, Ang I, Ang II and Ang-(1-7) levels were significantly higher in hypertensive CRF subjects when compared with normotensive CRF and healthy subjects (p < 0.05 for all comparisons). No differences were observed between normotensive CRF and healthy subjects. ESRD subjects exhibited a dramatic increase in Ang-(1-7) (25-fold higher than control values). In hypertensive CRF subjects, treatment with angiotensin-converting enzyme inhibitors (ACEi) increased (1.4-fold) plasma Ang-(1-7) and decreased (2.4-fold) Ang II. In ESRD, the use of ACEi produced a similar (1.5-fold) elevation of Ang-(1-7), but no changes in plasma Ang II. Our data showed different circulating RAS profiles between hypertensive and in normotensive CRF subjects. Marked changes in plasma Ang-(1-7) were associated with the presence of hypertension and progression of kidney dysfunction.
本研究的目的是评估血浆肾素活性(PRA)和血管紧张素(Ang)水平[Ang I、Ang II和Ang-(1-7)],以检测不同形式和阶段的慢性肾衰竭(CRF)患儿肾脏疾病中的循环肾素-血管紧张素系统(RAS)。受试者分为以下几组:32名血压正常的健康受试者、23名血压正常的CRF受试者、34名高血压CRF受试者和21名终末期肾病(ESRD)受试者。对所有受试者进行了PRA(ngAngI/mL/h)和血管紧张素(pg/mL)测量的放射免疫分析。与血压正常的CRF受试者和健康受试者相比,高血压CRF受试者的PRA、Ang I、Ang II和Ang-(1-7)水平显著更高(所有比较的p<0.05)。血压正常的CRF受试者和健康受试者之间未观察到差异。ESRD受试者的Ang-(1-7)显著升高(比对照值高25倍)。在高血压CRF受试者中,用血管紧张素转换酶抑制剂(ACEi)治疗可使血浆Ang-(1-7)升高(1.4倍),使Ang II降低(2.4倍)。在ESRD中,使用ACEi可使Ang-(1-7)产生类似的升高(1.5倍),但血浆Ang II无变化。我们的数据显示,高血压和血压正常的CRF受试者之间的循环RAS谱不同。血浆Ang-(1-7)的显著变化与高血压的存在和肾功能障碍的进展有关。